Novo drops ‘Nordisk’ in corporate refresh to take on Lilly in the weight-loss wars

Novo Nordisk, the Danish pharmaceutical powerhouse known for its diabetes drug Ozempic, is rebranding itself as simply "Novo" and making strategic moves to directly challenge Eli Lilly in the growing weight-loss drug market. This shift signals Novo's aggressive intent to capture a larger share of the booming weight-loss drug sector, where both companies have seen skyrocketing demand due to the rising global obesity epidemic. The rebranding also underscores a broader effort to diversify beyond diabetes treatments and solidify its position as a leader in new, high-growth medical fields.